Efficacy and safety of dopamine agonists in patients treated with antipsychotics and presenting a macroprolactinoma.

Conclusions: Even if the DA efficacy on PRL levels and tumor volume in patients with macroprolactinoma under antipsychotic drugs is less impressive than that typically observed, it may be considered satisfactory for half of our patients, particularly in cases of optic chiasm compression. Psychotic exacerbation was unusual in these patients, occurring mostly in those with the most severe psychotic forms. DAs may therefore be used as antitumor treatment for macroprolactinoma in patients with visual involvement, severe headaches or invasion into the skull base who receive antipsychotics. PMID: 32583656 [PubMed - in process]

https://www.ncbi.nlm.nih.gov/pubmed/32583656?dopt=Abstract

Source: European Journal of Endocrinology - June 26, 2020 Category: Endocrinology Authors: Allard L, Albarel F, Bertherat J, Caron PJ, Cortet C, Courtillot C, Delemer B, Jublanc C, Maiter D, Nunes ML, Raverot G, Sarfati J, Salenave S, Corruble E, Choucha W, Chanson P Tags: Eur J Endocrinol Source Type: research